Modra Pharmaceuticals Expands Management Team and Provides Corporate Update

19 december 2018

-- Colin Freund has joined as CEO --

-- Dr. Edwin De Wit appointed Head of Oncology Development --

-- Dr. Alan Barge appointed Chairman of the Supervisory Board --

-- Modra awarded EUR 2.8 million Innovation Credit from Dutch Government --


Amsterdam, The Netherlands, December 19, 2018 – Modra Pharmaceuticals B.V.

(“Modra”) today announced several additions to the management team and Supervisory

Board: Colin Freund has joined as Chief Executive Officer, Dr. Edwin De Wit as Head of

Oncology Development and Dr. Alan Barge as Chairman of the Supervisory Board. Eric

van der Putten, formerly interim-CEO, has transitioned into the role of Director at the

company. Modra continues to advance its pipeline of novel oral formulations of

chemotherapeutics with lead candidate ModraDoc006/r nearing completion of a Phase

Ib/IIa study in metastatic castrate-resistant prostate cancer (mCRPC).


Separately, Modra has received an Innovation Credit award of EUR 2.8 million from the

Dutch government. The credit from the RVO, an agency executing programs for the

Dutch Ministry of Economic Affairs, will be applied to further the clinical development of

ModraDoc006/r in prostate cancer.


“It is exciting to announce these positive developments for Modra, as we seek to

expand and accelerate Modra’s development programs. I am very grateful to Eric both

for a smooth transition and his continued contributions to the company,” commented

Colin Freund, CEO of Modra. “The company’s unique approach to developing oral

alternatives to classic intravenous taxanes has the potential to overcome many of the

challenges encountered with these therapies, the standard of care for thousands of

cancer patients annually. The recent Innovation Credit award is a validation of the

potential of Modra’s approach and therapeutic programs.”


Colin Freund has over 20 years’ experience in the pharmaceutical and biotechnology

industries, with a primary focus in oncology. Prior to joining Modra Pharmaceuticals,

Colin was Chief Executive Officer, QUE Oncology, Inc., which focused on the

development of several early-stage anti-cancer therapies. Before that, Colin served as

the Chief Business Officer at Transgene SA and also held senior management positions

at GPC Biotech AG and Doubletwist Inc. In these positions, Colin was responsible for

acquiring over $500 million in multiple licensing and M&A transactions. Colin received

his M.A. in Economics and Management Studies from the University of Cambridge,

U.K., and his M.B.A. from Stanford University, U.S.


Dr. Alan Barge commented: “We are delighted that Colin has joined Modra to advance

our shared vision of developing safe and effective treatment options that can improve

the outcomes and quality of life for many cancer patients, while also reducing the

burden on healthcare systems. The Board would like to thank Eric van der Putten for his

leadership and are very fortunate to have him continuing to contribute to Modra as a



Dr. Alan Barge’s experience in biotechnology and in oncology spans over 30 years. He

co-founded Carrick Therapeutics and ASLAN Pharmaceuticals. Prior to this, at

AstraZeneca, he served as Vice President and Head of Oncology and Infection, and

European and Global Medical Director at Amgen. Alan trained in medicine at the

University of Oxford and The London Hospital Medical College specializing in

hematology and oncology.


Dr. Edwin De Wit joined Modra from Celsion Corp., where he was the Senior Vice

President and Head of Medical for Europe since 2015. Dr. De Wit has over 20 years of

experience in clinical operations and research in the pharma and biotech industry and

has held leadership roles in oncology clinical development at Onyx Pharmaceuticals,

Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer. His specialties include the

design and implementation of strategic clinical development and medical affairs plans of

novel anti-cancer agents in various stages of development.


About ModraDoc006/r

ModraDoc006 is a proprietary optimized tablet formulation of the widely-used

chemotherapy drug docetaxel. ModraDoc006 is given in combination with ritonavir (r),

which acts as a booster to increase the systemic bioavailability of ModraDoc006.

ModraDoc006/r combines the convenience and practicality of one day per week treatment

at home, together with an improved safety profile and the potential for improved efficacy,

as compared to classical chemotherapy which is administered intravenously in a hospital



About Modra Pharmaceuticals

Modra Pharmaceuticals is contributing to modern cancer treatment options by designing

and developing oral versions of IV taxane chemotherapies with a substantially improved

therapeutic index. Our pipeline includes two of the most broadly used chemotherapies,

docetaxel and paclitaxel, both of which are in clinical development. Our vision is to work

together with cancer leaders and innovators to be an integral part of the rapidly evolving

landscape of combination therapy.




Colin Freund

CEO, Modra Pharmaceuticals

Tel: +1 609 933 8008


Trophic Communications

Gretchen Schweitzer or Dr. Jacob Verghese or

Tel: +49 (0) 89 2388 7735 or +49 (0) 89 2388 7731


Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
Read more

Modra's Unique Approach

improving patient lives    
Learn more


Meet us at one of the following events:      
Read more